Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ketorolac Tromethamine Tablets USP, 10 mg, is a nonsteroidal anti-inflammatory drug (“NSAID”) indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level and only as con...
Product Name : Ketorolac-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Rayner
Deal Size : $1,326.0 million
Deal Type : Divestment
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
Details : Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.
Product Name : Omidria
Product Type : Other Small Molecule
Upfront Cash : $126.0 million
June 02, 2023
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Rayner
Deal Size : $1,326.0 million
Deal Type : Divestment
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Neumentum
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : NTM-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2022
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Neumentum
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : DRI Healthcare
Deal Size : $188.4 million
Deal Type : Agreement
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
Details : Under the Royalty Purchase Agreement, DRI is entitled to royalties on net sales of OMIDRIA (having phenylephrine) received between September 1, 2022 and December 31, 2030, subject to annual caps.
Product Name : Omidria
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 10, 2022
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : DRI Healthcare
Deal Size : $188.4 million
Deal Type : Agreement
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Rayner
Deal Size : $1,326.0 million
Deal Type : Divestment
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
Details : As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.
Product Name : Omidria
Product Type : Other Small Molecule
Upfront Cash : $126.0 million
December 23, 2021
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Rayner
Deal Size : $1,326.0 million
Deal Type : Divestment
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Ache Laboratorios Farmaceuticos SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nemera's multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug that is used to treat moderately severe pain and inflammation, usually aft...
Product Name : Clilon
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2021
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Ache Laboratorios Farmaceuticos SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Rayner
Deal Size : $1,325.0 million
Deal Type : Divestment
Details : As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.
Product Name : Omidria
Product Type : Other Small Molecule
Upfront Cash : $125.0 million
February 12, 2021
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Rayner
Deal Size : $1,325.0 million
Deal Type : Divestment
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Rayner Surgical Group Limited
Deal Size : $1,000.0 million
Deal Type : Agreement
Details : As part of the agreement, Rayner will acquire the OMIDRIA commercial organization, including the OMIDRIA sales force. Rayner plans to expand the sales force in both the U.S. and ex-U.S., and further accelerating U.S. market growth of OMIDRIA.
Product Name : Omidria
Product Type : Other Small Molecule
Upfront Cash : $125.0 million
February 12, 2021
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Rayner Surgical Group Limited
Deal Size : $1,000.0 million
Deal Type : Agreement
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Nuance Pharma
Deal Size : $53.0 million
Deal Type : Licensing Agreement
Details : The licensing agreement provides Nuance with the exclusive rights to develop and commercialize Neumentum’s novel ketorolac for IV infusion (NTM-001) in China.
Product Name : NTM-001
Product Type : Other Small Molecule
Upfront Cash : $3.0 million
October 21, 2020
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Nuance Pharma
Deal Size : $53.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data to be presented include the final study results from four cohorts of a randomized, controlled clinical trial evaluating NTM-001, a novel, alcohol-free 24-hour continuous infusion formulation of the well-established potent NSAID analgesic ketorol...
Product Name : NTM-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2020
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable